Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine

BACKGROUND: The four co-circulating and immunologically interactive dengue virus serotypes (DENV1-4) pose a unique challenge to vaccine design because sub-protective immunity can increase the risk of severe dengue disease. Existing dengue vaccines have lower efficacy in DENV seronegative individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Odio, Camila D., Lowman, Kelsey E., Law, Melissa, Aogo, Rosemary A., Hunsberger, Sally, Wood, Brad J., Kassin, Michael, Levy, Elliot, Callier, Viviane, Firdous, Saba, Hasund, Chloe M., Voirin, Charlie, Kattappuram, Robbie, Yek, Christina, Manning, Jessica, Durbin, Anna, Whitehead, Stephen S., Katzelnick, Leah C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204028/
https://www.ncbi.nlm.nih.gov/pubmed/37221466
http://dx.doi.org/10.1186/s12879-023-08299-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204028/
https://www.ncbi.nlm.nih.gov/pubmed/37221466
http://dx.doi.org/10.1186/s12879-023-08299-5

Ejemplares similares